The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion ...

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...

Despite improvements in CPR and rates of getting patients to the hospital, only about 10 percent of people ultimately survive ...

The gross proceeds to the Company from the offering are approximately $2.8 million, before deducting the placement agent's ...

TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG ...

BioArctic AB (publ) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed ...

Base Therapeutics has announced that its NK510 cell injection, the world's first zero-off-target base-edited NK cell product, has received IND approvals from both the U.S. FDA and China's NMPA for ...

Despite improvements in CPR and rates of getting patients to the hospital, only about 10% of people ultimately survive after ...